In fact, the ability of FAK/PYK2 inhibitors to diminish leukemia-supportive myeloid cells as well as integrin signaling in T-ALL cells could be an added benefit of targeting this pathway. This evidence concerns the gene PTK2B and acute lymphoblastic leukemia.